Court Sanctions ImClone, IP Attorneys
“The questioning was...undertaken as part of a deliberate stratagem to deprive MIT of [the witness's] services,” the judge's decision said.
The suit was brought by the Massachusetts Institute of Technology and pharmaceutical company Repligen Corp. over ImClone's profitable cancer drug Erbitux. MIT...
To view the full article, register now.